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bstract
urpose:  Complete surgical resection is the standard treatment for localized breast phyllodes tumors. Post-surgical treatments are still a matter
f debate. We carried out an overview of the literature to investigate the clinical outcome of patients with phyllodes tumor. A retrospective
nalysis of mono-institutional series has been included as well.
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ethods:  We reviewed all the retrospective series reported from 1951 until April 2012. We analyzed cases treated at our institution from
999 to 2010.
esults:  Eighty-three articles (5530 patients; 1956 malignant tumors) were reviewed. Local recurrences were independent of histology.
istant recurrences were more frequent in the malignant tumors (22%). A total of 172 phyllodes tumors were included in the retrospective
nalysis.
iscussion:  Prognosis of phyllodes tumors is excellent. There are no convincing data to recommend any adjuvant treatment after surgery.
olecular characterization may well provide new clues to permit identification of active treatments for the rare poor prognosis cases.
 2013 Elsevier Ireland Ltd. All rights reserved.
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.  Introduction
Phyllodes tumor of the breast are rare neoplasms with an
ncidence <1% of all primary breast tumors [1]. In 1982,
he World Health Organization declared the term “phyllodes
umor” as the most appropriate among more than 60 syn-
nyms [2]. After Trevor, Norris and Azzopardi the World
ealth Organization sub-classified them histologically as
enign, borderline, or malignant [3–5]. Benign tumors are
ore frequent having an incidence of 35–64% while malig-
ant tumors comprise about 25% of cases [1,6,7]. The median
ge of occurrence of disease is 40–50 years [1,7,8]. Histolog-
cally, they are fibroepithelial tumors, likely originated from
he terminal ducto-lobular unit and considered as stroma-
erived [5]. Microscopically, the stromal component may be
land resembling that of fibroadenoma, or atypical, resem-
ling that of soft-tissue sarcoma, or it can vary between these
xtremes, often resembling low-grade sarcoma. Grading is
sually based on a semi-quantitative evaluation of the follow-
ng criteria in the stromal component: nuclear pleomorphism,
itotic rate, overgrowth, cellularity and aspects of tumor
argins. Ward firstly reported the presence of stromal over-
rowth as putative additional factor of prognosis [9]. In 1991
ohen-Cedermark included tumor necrosis and the presence
f stromal elements other than fibromyxoid tissue among the
rognostic factors [10].
Complete surgical resection offers high rates of local con-
rol and disease-free survival [1]. Mastectomy has recently
een replaced by conservative surgery with adequate negative
urgical margins [6,7,11–14]. The potential role of adju-
ant radiotherapy is still debated as only a minor fraction
f patients have received this treatment and also there is an
bsence of large prospective trials [1,12,15–17].
We carried out an overview of literature to investigate the
rognosis of phyllodes tumor according to tumor grade. We
ave also included a retrospective analysis of 172 consecutive
atients with this tumor from our institute.
.  Overview  of  the  literaturePlease cite this article in press as: Spitaleri G, et al. Breast phyllodes tum
analysis. Crit Rev Oncol/Hematol (2013), http://dx.doi.org/10.1016/j.cri
.1.  Methods
References were obtained from the major indexed litera-
ure database Medline, using the keywords breast phyllodes
E
o
s
flysis; Prognosis
umor. We reviewed all the cases of breast phyllodes tumors
eported from 1951 (after Trevis’ publication) until April
012 [4–84]. We included only the articles in English which
ocused on clinical reports convincingly documenting the
iagnosis, and which clearly reported the treatments admin-
stered and follow-up data. The analysis also included four
eports written in their original language since their abstract
eported all requested information [74–77].
.2.  Results
Eighty-three articles were reviewed with a total of 5530
atients (malignant 1956, 35%). Comprehensively, the mean
umber of patient per article was 67 (median 37.5; range
–605).
.2.1. Description  of  overall  results
Table 1 reports the most representative studies with about
ore than 75 patients. These retrospective analyses collected
ases treated in a period from 1930 to 2010. The mean size
as 7.3 cm (median 6.5, range 0.4–29). The mean rate of mas-
ectomies performed was 40% (range 0–67%). The median
ollow-up was 5 years (range 0.4–43). The mean local recur-
ence rate was 19.1% (median 17%; range 0–67%). The mean
istant recurrence rate was 8.9% (median 5%; range 0–39%).
able 2 summarizes the details of the analysis. Local recurr-
nces were independent of histology, but more frequent in
he malignant group. Distant recurrences are almost never
ncountered in the benign group, whilst they are rare for bor-
erline tumors (except for the report by Reinfuss [7] reporting
n incidence of 22%). The malignant group relapsed with a
ean and median rate of almost 25% (up to 60% in the 8 cases
escribed by Halverson [24] and in the 13 cases described by
awkins [43]). In the publications reporting positive surgi-
al margins the mean local recurrence rate reached 31.5%
median 14.5%; range 1–67%) [5–7; 10, 11, 14, 16, 18, 35,
8–40; 42–44; 48–57; 59, 60, 62–65; 67–71; 74, 75; 80–84].
ifty-eight progressions (from grade 1 or 2 to upper grade) out
f 3574 cases (benign + borderline) were described (1.6%).or: A review of literature and a single center retrospective series
trevonc.2013.06.005
ighteen (0.3%) bilateral cases were recorded. A number
f reports demonstrated the putative relationship between
tromal overgrowth and pathological features (proliferative
raction) or clinical outcome (local and distant relapse, or
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Table 1
Selected retrospective investigations on the management of phyllodes tumors of the breast. Pts = patients; size expressed in cm; M = mastectomy (%);
Mal. = malignant (number); LR locale recurrence (%); DR distant recurrence (%); Asia–Austr = Asia–Australia.
Author Year Period Pts Country Size M (%) Mal. LR DR
Treves 1951 1930–1949 77 USA 10 42 18 67.0 11.6
Norris 1967 Before 1967 94 USA 6.4 59 NR 35.0 NR
Hajdu 1976 1932–1976 199 USA 4 23 49 16.0 1.5
Briggs 1983 1960–1980 83 USA 5 12 3 0.0 0.0
Chua 1988 1978–1984 106 Singapore 5 8 3 19.0 0.9
Cohn-Cedermark 1991 1958–1986 77 Swedish 5 69 49 19.0 21.0
Grimes 1992 1983–1990 187 USA 4.4 NR 50 28.0 8.0
Zurrida 1992 1970–1989 216 Italy NR 9 14 12.5 NR
Reinfuss 1996 1952–1988 170 Poland 7 42 59 8.0 16.0
Zissis 1998 1981–1995 84 Greece 6 29 15 2.3 1.0
Chaney 2000 1944–1998 101 USA 6 53 29 4.0 8.0
Niezabitowski 2001 1952–1998 120 Poland NR 60 44 8.0 9.0
Tse 2004 1988–2001 179 Asia–Austr. 4.8 NR NR NR NR
Chen 2005 1985–2003 172 Taiwan 5.8 27 29 11.0 1.7
Tan 2005 1992–2002 335 Singapore 5.4 8 31 12.8 2.0
Abdalla 2006 1988–2003 79 Egypt 11 42 21 20.0 14.0
Ben hassouna 2006 1986–2001 106 Tunisia 8.3 23 28 12.2 7.5
Barrio 2007 1954–2005 293 USA 6 16 90 8.5 1.7
Guillot 2011 1994–2008 165 France 3 6 14 10.0 1.2
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Iimiento 2011 1999–2010 124 
an 2012 1992–2010 605 
verall survival) [9–11; 40, 42, 43, 49, 55, 57, 59, 63, 68,
0].
.2.2. Post-surgical  treatments
A total of 278 (14.2% of malignant cases) patients received
omplementary radiotherapy. The mean local recurrence rate
nd the median distant recurrence rate were 9% (mean 8%,
ange 0–22%) and 13.5% (mean 16.3, range 0–38%), respec-
ively, in the 6 studies where at least 15 patients (an arbitrary
ut-off chosen by the authors) had received radiotherapy
10, 12, 15–18; 75]. The median follow-up of these stud-
es was of 13.25 years (mean 16.2, range 4, 6–43). IndeedPlease cite this article in press as: Spitaleri G, et al. Breast phyllodes tum
analysis. Crit Rev Oncol/Hematol (2013), http://dx.doi.org/10.1016/j.cri
one of these studies proved that radiotherapy can affect
he distant spread of tumor and overall survival. Impor-
antly, Christensen did not reveal any difference in overall
able 2
atient demography and clinical outcome according to tumor histology.
atients (5530)
enign 2861 (52%)
orderline 713 (13%)
alignant 1956 (35%)
ean size (range) 7.3 cm (0.4–29)
edian size 6.5 cm
ean rate of mastectomy 40% (0–67%)
he mean local recurrence rate (median, range)
ll 19.1% (0–67)
enign 15% (12.5, 0–42)
orderline 17% (19, 0–50)
alignant 28% (21, 0–100)
he mean distant recurrence rate (median, range)
ll 8.9% (0–39%)
enign 0.1% (0; 0–2%)
orderline 0.2% (0; 0–33%)
alignant 22% (22; 0–62.5%)
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h4.5 NR 19 6.5 1.6
re 5.2 19 54 11.2 1.1
urvival between the group who was treated with radiotherapy
nd the group treated with surgery alone in a retrospective
eries [15]. In 2009 Barth published the first non-randomized
rospective trial of radiotherapy for 46 consecutive patients
ith malignant tumors and demonstrated that radiotherapy
an reduce the local recurrences (0%), although there were
wo distant metastases [17]. Chaney et al. compared in a
etrospective series the patients (6) treated with adjuvant
adiotherapy with other patients treated with surgery alone
23): the former had a lower risk of local relapse (9% at
0 years of follow up) [18]. This data was confirmed by an
ndian experience (Pandey et al.) where 25 out of 37 patients
eceived adjuvant radiotherapy. Unfortunately, 20 of the 37
atients had positive/unknown surgical margins and the actu-
rial local failure was 22%[16]. In our opinion this study
laces greater emphasis on the importance of negative mar-
ins than on the role of radiotherapy. Overall, only 72 patients
ere treated with chemotherapy (36 in adjuvant setting).
mong the four studies reporting adjuvant chemotherapy
he follow-up is too short (mean 2.6; median 2.1; range
–5.4 years) and indeed there was a higher rate of surgical
ositive margins (0.3–39%): the distant recurrence rate was
ot lower relative to the other publications with a range of
.2–40% [53,71,74,80]. The most significant trial is repre-
ented by that by Morales–Vasquez (a non-prospective trial)
hich demonstrated that the addition of adjuvant chemother-
py (doxorubicin/dacarbazine) to surgery did not reduce the
isk of disease recurrence [71].or: A review of literature and a single center retrospective series
trevonc.2013.06.005
.2.3. Biomarkers  involved  on  tumor  progression  from
broadenoma to  malignant  phyllodes  tumor
Numerous studies (preclinical or retrospective reports)
ave investigated some biomarkers that can be involved in
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Table 3
Molecular features which were described in tumor progression from benign to malignant tumor and could be putative prognostic factor. EGFR: epidermal growth
factor receptor; c-kit: kit oncogene; p16INK4a: cyclin-dependent kinase inhibitor 2A; Wnt5: similar to wingless-type MMTV integration site family, member
5B precursor; pRB: retinoblastoma protein; RASSF1A: Ras association (RalGDS/AF-6) domain family 1 protein; TWIST1: twist homolog 1 (Drosophila);
EPS15: EGFR pathway substrate 15; FA: fibroadenoma; PT: phyllodes tumor.
Molecule/pathway Mechanism Findings Reference (Ref N)
EGFR amplification EGFR/EPS15/caveolin-1 interplay in the
carcinogenesis
Preclinical Agelopoulos ′07 [85]
EGFR expression Progression to borderline/malignant Positive Tse ′09 [89]
Negative Yonemori ′06 [61]
C-kit expression Progression to borderline/malignant Positive Noronha ′11 [93]
Esposito ′06 [62]
Negative Yonemori 2006 [61]
C-kit mutations A ‘druggable target’ Negative Bose ′10 [91]
Increased number of
chromosomal gains (e.g4q12)
Progression to borderline/malignant Positive Lu ′08 [86]
9p deletion (loss of
p16INK4a)
Progression to borderline/malignant Positive Jones ′08 [87]
Wnt5a expression Role for progression and epithelial/stromal
interactions
Positive Karim ′09 [88]
Stromal p16 and
stromal/epithelial pRb
expression
Progression to borderline/malignant Positive Karim ′10 [90]
Methylation of RASSF1A
a
Progression from FA to PT Positive Huang ′10 [92]; Kwon ′11 [94]
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retrieved. Patients treated in our institution (167) and those
referred for consultation (5) to our site from other hospi-
tals were included in the analysis (Table 4). There were 68
Table 4
Patient demographics (EIO series).
Patients (172) (%)
Age (median years) 44
Age (range years) 11–82
Female/male 175/1
Histology
Benign phyllodes 68 (39.5)
Borderline phyllodes 42 (24.5)
Malignant phyllodes 62 (36)
Size
≤2 cm 19 (11.9)
2- ≤ 5 cm 82 (51.6)
>5 cm 58 (36.5)
Not available 13
Surgery
Mastectomy 35 (20)
Conservative 137 (80)nd TWIST1
D10 expression Prediction of occurrence of met
umor progression from fibroadenoma to malignant phyl-
odes tumor (Table 3) [61,85–95]. Most were focus on the
ole of Epidermal Growth Factor Receptor, c-kit and Wnt
athways: unfortunately they produced almost contrasting
esults.
.  Retrospective  series
.1.  Methods
Data from 172 patients with breast phyllodes tumors (out
f 203 patients with all breast sarcomas) [96] treated at the
uropean Institute of Oncology in Milan from 1999 to 2010
ere collected retrospectively. Diagnosis was confirmed his-
ologically on the surgical specimens. Stromal overgrowth
as defined as an absence of ductal elements in a 40×
ow-power field. Follow-up was obtained by internal data
ase clinical collection and interviews. The principal end-
oint was 10-year cumulative incidence of phyllodes-specific
vents. Disease-related events were defined as: ipsilateral
reast recurrence, recurrence in the breast and axilla, and
istant metastases. Secondary end-points included 10-year
umulative incidence of specific-phyllodes deaths and over-
ll survival. Cumulative incidences were compared across
ifferent subgroups by means of the Gray test [97]. Multivari-
te Cox proportional hazards regression models were used
o identify the prognostic independent clinico-pathologicalPlease cite this article in press as: Spitaleri G, et al. Breast phyllodes tum
analysis. Crit Rev Oncol/Hematol (2013), http://dx.doi.org/10.1016/j.cri
arameters associated with the risk of phyllodes-related
vents. The variables which showed some statistical signifi-
ance (P < 0.10) in the overall univariate analysis were tested
n the multivariable model with a forward selection method.
A
C
RPositive Al-Masri ′11 [95]
djusted hazard ratios (HR) with 95% confidence intervals
CIs) were reported. All analyses were carried out with the
AS software (SAS Institute, Cary, NC) and the R software
http://cran.r-project.org/). All the reported P-values were
wo sided.
.2.  Results
From 1999 to 2010 172 cases with phyllodes tumor wereor: A review of literature and a single center retrospective series
trevonc.2013.06.005
djuvant treatments
hemotherapy 3 (1.7)
adiotherapy 9 (5.0)
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Fig. 1. Cumulative incidence of phyllodes-related events by histotype.
Breast-related events: (a) Benign phyllodes tumor group: ipsilateral breast
recurrence (n = 3); (b) borderline malignant phyllodes tumor group: ipsi-
lateral breast recurrence (n = 6); (c) malignant phyllodes tumor group:
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ppsilateral breast recurrence (n = 8), recurrence in the breast and axilla (n = 1),
istant metastases (n = 2).
enign, 42 borderline and 62 malignant phyllodes. Median
ollow-up was 85 months (4.5–268 months). Most of the
atients (137, 80%) underwent conservative surgery, while
5 (20%) underwent mastectomy, of which 20 benefited
rom breast reconstruction. We observed 20 phyllodes-related
rst events: 17 local recurrences, one chest-wall involvement
nd two distant events. The 10-year cumulative incidence of
hyllodes-related events was 16.6% (95% CI 9.7–27.2). Four
hyllodes-related deaths and 3 deaths from other causes were
bserved. The 10-year cumulative incidence of phyllodes-
elated deaths was 2.5% (95% CI 0.9–6.6%). The 10-year
verall survival was 94.6% (95% CI 88.5–97.5%).
.2.1.  Benign  tumors
Figs. 1 and 2 depict the 10-year cumulative incidence of
hyllodes-related events according to tumor grade and the
0-year cancer-specific survival according to tumor grade,
espectively. Sixty-eight (39.5%) cases out of 172 were
enign. All but three of them underwent conservative surgery.
e recorded three (4.5%) events among these patients and
ll consisted of local recurrences which were well managed
ith further surgery. Two patients died from causes unrelated
o the tumor.Please cite this article in press as: Spitaleri G, et al. Breast phyllodes tum
analysis. Crit Rev Oncol/Hematol (2013), http://dx.doi.org/10.1016/j.cri
.2.2.  Borderline  tumors
Forty-two (24.5%) patients had a borderline tumor. About
0% of the patients underwent breast-sparing surgery. We
(
m
nig. 2. Cumulative incidence of phyllodes-related deaths by histotype.
ecorded 6 (14.2%) events out of these 42 patients and all
onsisted of local recurrences treated either with conservative
urgery or mastectomy. All patients were alive at the analysis
ut-off except for one who died from head and neck cancer.
.2.3. Malignant  tumors
Sixty-two (36%) patients had a malignant phyllodes
umor. Thirty-seven patients (59.6%) were treated with a
onservative approach. Two patients with malignant phyl-
odes with unfavorable features received 5 courses of
pirubicin/ifosfamide. Eight patients with the same fea-
ures received radiotherapy after radical surgery. One patient
eceived both chemotherapy and radiotherapy. None of these
atients relapsed after a median follow-up of 3.5 years (range
.5–10). Thirteen (21%) events were recorded in 11 (17.7%)
f 62 patients. These consisted of 8 (13%) local recurren-
es, 1 (1.6%) chest wall infiltration and four (6.5%) distant
etastases. Four patients died from disease progression (3
ith a metastatic disease, one for a chest wall infiltration).
he 10-year phyllodes-specific survival was 92.6%.
.2.4. Uni-  and  multi-variate  analyses
Univariate analysis (Table 5) identified age as a progno-
tic factor for all phyllodes-related events, with the risk
ecreasing with increasing age. The subgroup of malignant
umors showed a similar trend, but the association was not
tatistically significant. Presence of necrosis, stromal over-
rowth and positive surgical margins were putative negative
rognostic factors for recurrence in the overall populationor: A review of literature and a single center retrospective series
trevonc.2013.06.005
P < 0.10). Despite the sparse number of events, surgical
argin status was a significant prognostic factor in the malig-
ant tumor subgroup. In the multivariable analysis (Table 6),
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Table 5
Uni-variate analysis for phyllodes-related events for all patients and according to tumor grade.
All Benign Borderline
malignant
Malignant
No. (%) Events
(10-year cum
inc%)
No. (%) Events
(10-year cum
inc%)
No. (%) Events
(10-year cum
inc%)
No. (%) Events
(10-year cum
inc%)
P
Age Total 172 20 (16.6) 68 3 (8.5) 42 6 (15.9) 62 11 (27.3)
<35 35 (20.4) 9 (37.6) 0.01 15 (22.1) 1 (7.7) 0.56 8 (19.0) 4 (50.0) <0.01 12 (19.4) 4 (54.5) 0.29
35–49 83 (48.3) 7 (15.5) 37 (54.4) 2 (14.6) 23 (54.8) 1 (5.0) 23 (37.1) 4 (20.0) 0.12c
≥50 54 (31.4) 4 (8.6) 16 (23.5) 0 (0.0) 11 (26.2) 1 (9.1) 27 (43.6) 3 (14.1)
Tumor size a ≤2 cm 20 (12.0) 2 (20.8) 0.88 14 (20.6) 2 (22.6) 0.25 3 (7.3) 0 (0.0) 0.51 3 (5.2) 0 (0.0) 0.70
2.1–5 cm 85 (50.9) 11 (15.0) 39 (57.4) 1 (2.9) 21 (51.2) 4 (22.2) 25 (43.1) 6 (27.6)
>5 cm 62 (37.1) 7 (18.2) 15 (22.1) 0 (0.0) 17 (41.5) 2 (13.2) 30 (51.7) 5 (35.6)
Necrosis a No 161 (94.2) 16 (15.2) 0.09 68 (100.0) 3 (8.5) – 41 (97.6) 6 (16.3) 0.67 52 (85.3) 7 (24.9) 0.23
Yes 10 (5.9) 3 (31.7) 0 (0.0) – 1 (2.4) 0 (0.0) 9 (14.7) 3 (35.6)
Overgrowth a No 104 (68.0) 8 (11.6) 0.07 58 (93.6) 3 (9.7) 0.74 29 (80.6) 4 (15.3) 0.32 17 (30.9) 1 (7.7) 0.18
Yes 49 (32.0) 8 (26.8) 4 (6.4) 0 (0.0) 7 (19.4) 0 (0.0) 38 (69.1) 8 (34.5)
Surgical margins a,b Negative 161 (94.2) 16 (15.1) 0.09 67 (98.5) 2 (7.0) <0.01 39 (95.0) 5 (14.5) 0.57 55 (88.7) 9 (28.6) 0.74
Positive 10 (5.9) 3 (30.0) 1 (1.5) 1 (100.0) 2 (5.0) 0 (0.0) 7 (11.3) 2 (28.6)
Surgery BCS 137 (79.7) 14 (14.1) 0.21 65 (95.6) 3 (8.6) 0.75 35 (88.1) 6 (19.5) 0.21 37 (59.7) 5 (17.1) 0.22
Mastectomy 35 (20.3) 6 (28.9) 3 (4.4) 0 (0.0) 7 (11.9) 0 (0.0) 25 (40.3) 6 (43.5)
a Information was missing for one or more patients.
b Tumor present on the surgical margin (n = 5) or within 1 mm or less from the margin (n = 5).
c Testing the trend. BCS: breast conservative surgery. Breast-related events: (a) benign phyllodes tumor group: ipsilateral breast recurrence (n = 3); (b) borderline malignant phyllodes tumor group: ipsilateral
breast recurrence (n = 6); (c) malignant phyllodes tumor group: ipsilateral breast recurrence (n = 8), recurrence in the breast and axilla (n = 1), distant metastases (n = 2).
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Table 6
Multivariate survival analysis of tumor-related events.
Parameters HR (95% C.I.)
Age (years) <35 vs ≥50 5.4 (1.5–19.6)
N
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e
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r
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r
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r
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s
t
o
h
w
t
r
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s
a
a
a
p
i
o35–49 vs ≥50 1.5 (0.4–5.5)
ecrosis Present vs absent 3.9 (1.1–14.1)
urgical margins Positive vs negative 3.9 (1.1–14.3)
oung age (<35 years), presence of necrosis and positive sur-
ical margins were associated with a significant increase of
isk of phyllodes-related events. When limiting the analysis
o borderline and malignant phyllodes, age remained the only
ignificant prognostic factor.
.  Discussion
This is an overview of the English literature since 1951
ith a total of 5530 patients and a median follow-up of 5
ears. This overview is augmented with a presentation of
ew 172 cases of breast phyllodes treated at our Institution
rom 1999 to 2010 with a median follow-up of 7 years.
This tumor is clearly more frequent in women: in our
eries, there was only one case in a man, few cases have been
eported in men and these have invariably been associated
ith gynecomastia [23,98].
Multi-focality (2–5 lumps) has been variably reported
n literature where the highest incidence (up to 12%) was
eported by Ben hassouna [65], whereas bilateral cases are
are being from 0 to 3.5% [70]. In our series we did not
ncounter multi-focality or bilateral cases.
Regarding the distribution of histology: benign tumors
re more frequent (52% in the literature, about 40% in our
eries). The risk of local recurrence is irrespective of histol-
gy, although the events are more frequent in the malignant
nd borderline tumors than in benign group. Among the
enign and borderline tumors all local relapses can be well
anaged by further surgery (either breast-conserving surgery
r mastectomy). In this group (benign/borderline) positive
urgical margins do not seem to predict a worse outcome.
wo aspects must be taken in account during the recurrence
fter resection of benign or borderline tumor: the risk of
istant recurrence and the sarcomatous progression (from
enign/borderline to malignant tumor). The risk of distant
elapse is very low (<0.5% in the literature, no events in our
eries). Tumor progression has been reported with wide range
f percent (3–33%) in different reports with a median of 4%
3,4,7,18,20,23,25,27,32,59,65,70]. The highest incidence of
vents was reported in a small series [25], whereas the largest
eries reported a lower incidence (3%) [59,65,70]. Accord-
ngly, the standard treatment for these tumors is a breast
onserving surgery with negative margins. Based on the fact
hat local recurrences are usually well managed with breastPlease cite this article in press as: Spitaleri G, et al. Breast phyllodes tum
analysis. Crit Rev Oncol/Hematol (2013), http://dx.doi.org/10.1016/j.cri
paring surgery and that the risk of tumor progression is low,
 policy of ‘wait and see’ should be safely considered in cases
ith positive surgical margins, as already stated by Zurrida
14].
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Different aspects are encountered in the malignant group,
here there is a higher incidence of local relapse (about 30%
oth in the literature and in our series) and there is the chance
f distant relapse: in our series we recorded one chest wall
nvolvement and four distant metastases (6.4%) with four
hyllodes-related deaths. In the literature overview the risk
f systemic spread for malignant tumors was higher (22%).
n any case, the extent of surgery did not affect long-term sur-
ival, so far the main standard of treatment is represented by
reast spearing surgery (when feasible according to tumor
nd breast dimensions) with mandatory surgical negative
argins. The role of adjuvant radiotherapy is also a matter
f debate. In our series only nine patients received adjuvant
adiotherapy and none of them relapsed. In the literature,
adiotherapy has been shown to reduce the risk of local but
ot of distant relapse in malignant tumors. All these reports,
owever, were retrospective series with the exception of the
tudy by Barth [10,12,15–18;75]. At this time, the indication
or radiotherapy should be limited to patients with malig-
ant tumors and positive surgical margins when a surgical
adicalization cannot be performed.
The role of adjuvant chemotherapy is even more question-
ble and it is not indicated [71].
Beyond histology, different parameters (clinical or molec-
lar) has been investigated to predict a higher risk of relapse.
n our series, according to the multivariable analysis, young
ge (<35 years), tumor necrosis and positive surgical margins
ere associated with a significant increase of phyllodes-
elated events. Many reports dealt with young age as a
utative prognostic factor [4,20–22,33,99]. Except for the
eport by Chua [34], all other studies identified young age as
 favorable prognostic factor contrary to our data.
In the near future, the molecular characterization of
hese unusual breast tumors might well allow the identi-
cation of high risk tumors for distant relapse. Numerous
tudies have attempted to determine whether immunohis-
ochemical markers may be useful to predict the clinical
utcome of the patients, but so far all these markers
ave failed to attain any clinical validation [61,85–95]. It
ould be also extremely important to identify ‘druggable
argets’ for this type of tumor, that it is notably chemo-
efractory.
In conclusion, we confirm that the prognosis of benign and
orderline phyllodes tumors is excellent. They are cured with
urgery alone. Most, but not all malignant phyllodes tumors
lso have a good prognosis. The main standard of treatment is
dequate surgery with negative margins. No convincing data
re available to suggest any adjuvant treatment. For the rare
oor prognosis tumors in the near future molecular character-
zation may well provide new clues to permit identification
f more active treatments.or: A review of literature and a single center retrospective series
trevonc.2013.06.005
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